...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinics and research in hepatology and gastroenterology >Thymosinβ4: A novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient?
【24h】

Thymosinβ4: A novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient?

机译：胸腺素β4：急性慢性肝功能衰竭患者预后的新型评估生物标志物？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and aim: In the previous study, we found serum thymosin β4 (Tβ4) levels were associated with mortality in liver failure patients. In this study, we try to evaluate the prognostic value of Tβ4 in acute-on-chronic liver failure (AoCLF) patients by comparing with the Child-Pugh (CTP) and Model for End-Stage Liver Disease (MELD) scores. Methods: Serum Tβ4 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the CTP and MELD scores were calculated for each patient. Results: Serum Tβ4 levels of AoCLF patients [0.4120 (0.2447-0.7492). μg/mL] were lower than healthy controls [9.2710 (5.1660-13.2485). μg/mL] (P<. 0.001). AoCLF patients were divided into survival and death group. Compared to survivors, lower Tβ4 concentrations, higher CTP and MELD scores (P<. 0.001, respectively) were observed in AoCLF patients who died. There were negative correlations between Tβ4 levels and CTP scores (P<. 0.001), MELD scores (P<. 0.001). A CTP score of 11.5, a MELD score of 21.63 and a Tβ4 concentration of 0.3840. μg/mL were identified as the cut-off values for the stratification of AoCLF patients. MELD. ≥. 21.63 combined with Tβ4. <. 0.3840. μg/mL can more exactly discriminate between the patients who would survive and die. Conclusions: Serum Tβ4 concentration has appreciable value to evaluate the short-term prognosis of AoCLF patients, although Tβ4 is not superior to MELD. The combination of Tβ4 and MELD scores are more effective in assessing the prognosis of AoCLF patients.
机译：背景与目的：在先前的研究中，我们发现血清胸腺肽β4（Tβ4）水平与肝衰竭患者的死亡率相关。在这项研究中，我们试图通过与Child-Pugh（CTP）和终末期肝病模型（MELD）得分进行比较，评估Tβ4在急性慢性肝功能衰竭（AoCLF）患者中的预后价值。方法：采用酶联免疫吸附试验（ELISA）检测血清Tβ4水平，并计算每位患者的CTP和MELD评分。结果：AoCLF患者的血清Tβ4水平[0.4120（0.2447-0.7492）。 [μg/ mL]低于健康对照组[9.2710（5.1660-13.2485）。 [μg/ mL]（P ＜0.001）。 AoCLF患者分为生存和死亡组。与幸存者相比，在死亡的AoCLF患者中观察到较低的Tβ4浓度，较高的CTP和MELD评分（分别为P <.0.001）。 Tβ4水平与CTP评分（P <.0.001），MELD评分（P <.0.001）之间呈负相关。 CTP评分为11.5，MELD评分为21.63，Tβ4浓度为0.3840。将μg/ mL确定为AoCLF患者分层的临界值。融合。 ≥。 21.63与Tβ4结合。 <。 0.3840。 μg/ mL可以更准确地区分存活和死亡的患者。结论：血清Tβ4浓度对AoCLF患者的短期预后有一定价值，尽管Tβ4并不优于MELD。 Tβ4和MELD评分的结合在评估AoCLF患者的预后方面更为有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号